TWI808092B - 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 - Google Patents

作為干擾素基因調節劑之刺激劑的環狀二核苷酸 Download PDF

Info

Publication number
TWI808092B
TWI808092B TW107130419A TW107130419A TWI808092B TW I808092 B TWI808092 B TW I808092B TW 107130419 A TW107130419 A TW 107130419A TW 107130419 A TW107130419 A TW 107130419A TW I808092 B TWI808092 B TW I808092B
Authority
TW
Taiwan
Prior art keywords
compound
formula
pharmaceutically acceptable
hydrate
acceptable salt
Prior art date
Application number
TW107130419A
Other languages
English (en)
Chinese (zh)
Other versions
TW201919650A (zh
Inventor
運濤 宋
曉齊 陳
李安蓉
Original Assignee
中國大陸商北京軒義醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中國大陸商北京軒義醫藥科技有限公司 filed Critical 中國大陸商北京軒義醫藥科技有限公司
Publication of TW201919650A publication Critical patent/TW201919650A/zh
Application granted granted Critical
Publication of TWI808092B publication Critical patent/TWI808092B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
TW107130419A 2017-08-30 2018-08-30 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 TWI808092B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762552148P 2017-08-30 2017-08-30
US62/552,148 2017-08-30
US201862660565P 2018-04-20 2018-04-20
US62/660,565 2018-04-20

Publications (2)

Publication Number Publication Date
TW201919650A TW201919650A (zh) 2019-06-01
TWI808092B true TWI808092B (zh) 2023-07-11

Family

ID=65527221

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107130419A TWI808092B (zh) 2017-08-30 2018-08-30 作為干擾素基因調節劑之刺激劑的環狀二核苷酸

Country Status (14)

Country Link
US (1) US11773132B2 (enExample)
EP (1) EP3692048A4 (enExample)
JP (1) JP7311514B2 (enExample)
KR (1) KR102782200B1 (enExample)
CN (1) CN111263767B (enExample)
AU (1) AU2018323053A1 (enExample)
BR (1) BR112020004047A2 (enExample)
CA (1) CA3073919A1 (enExample)
IL (1) IL272928A (enExample)
MX (1) MX2020002303A (enExample)
RU (1) RU2020112502A (enExample)
SG (1) SG11202001847WA (enExample)
TW (1) TWI808092B (enExample)
WO (1) WO2019043634A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060396T2 (hu) 2016-03-18 2023-02-28 Immune Sensor Llc Ciklikus DI-nukleotid vegyületek és azok felhasználási módszerei
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
CA3053568A1 (en) 2017-02-21 2018-08-30 Board Of Regents, The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
AU2018323053A1 (en) 2017-08-30 2020-03-19 Beijing Xuanyi Pharmasciences Co., Ltd Cyclic di-nucleotides as stimulator of interferon genes modulators
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
JP7250808B2 (ja) * 2018-03-08 2023-04-03 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
KR20210015937A (ko) 2018-06-01 2021-02-10 에자이 알앤드디 매니지먼트 가부시키가이샤 방광암을 치료하기 위한 방법
WO2020074004A1 (zh) * 2018-10-12 2020-04-16 上海济煜医药科技有限公司 环二核苷酸类化合物及其应用
WO2021013234A1 (en) * 2019-07-25 2021-01-28 Beigene, Ltd. Cyclic dinucleotides as sting agonists
KR20220150356A (ko) * 2020-03-06 2022-11-10 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 치료제 및 이의 접합체
JPWO2021206158A1 (enExample) 2020-04-10 2021-10-14
CN111592570B (zh) * 2020-05-15 2022-04-29 清华大学 新型sting激动剂及其制备方法和应用
WO2022083584A1 (zh) * 2020-10-20 2022-04-28 泰励生物科技（上海）有限公司 多功能环二核苷酸及其用途
KR102466750B1 (ko) * 2020-10-23 2022-11-15 아주대학교산학협력단 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096174A1 (en) * 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
TW201831192A (zh) * 2016-11-25 2018-09-01 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
PT1572106E (pt) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Métodos para prevenção e tratamento de metástase de cancro e perda óssea associada a metástase de cancro
US20060167241A1 (en) 2003-07-15 2006-07-27 Mitsui Chemicals, Inc. Method for synthesizing cyclic bisdinucleoside
WO2005030186A2 (en) 2003-07-28 2005-04-07 Univ Maryland Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
JP4931798B2 (ja) 2004-03-15 2012-05-16 ケイ．アール． カラオリス，デイヴィッド 免疫、炎症または神経保護応答のための方法
GEP20125612B (en) 2006-08-18 2012-08-27 Novartis Ag Prlr-specific antibody and usage thereof
DK2242512T3 (en) 2008-01-15 2016-06-06 Univ Leland Stanford Junior Method for manipulating phagocytosis mediated by CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CA2754127C (en) 2009-03-02 2017-04-18 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
HUE031855T2 (en) 2010-08-20 2017-08-28 Novartis Ag Anti-epidermal growth factor receptor 3 (HER3) antibodies
WO2014093936A1 (en) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
MX374828B (es) 2013-04-29 2025-03-06 Memorial Sloan Kettering Cancer Center Composiciones y metodos para alterar la señalizacion del segundo mensajero.
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
HK1223794A1 (zh) 2013-10-21 2017-08-11 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
CA2931146C (en) 2013-11-22 2022-06-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US10450341B2 (en) 2014-06-04 2019-10-22 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of STING
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112017018908A2 (pt) * 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
CN108137641B (zh) * 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
US10906930B2 (en) 2015-10-28 2021-02-02 Chinook Therapeutics, Inc. Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
PT3402801T (pt) 2016-01-11 2025-10-23 Innate Tumor Immunity Inc Dinucleótidos cíclicos para o tratamento de condições associadas à atividade de sting, tal como cancro
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
HUE060396T2 (hu) 2016-03-18 2023-02-28 Immune Sensor Llc Ciklikus DI-nukleotid vegyületek és azok felhasználási módszerei
EP3448393A1 (en) * 2016-04-25 2019-03-06 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018045204A1 (en) 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
WO2018065360A1 (de) * 2016-10-07 2018-04-12 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
AU2017378783A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
EP3558327A4 (en) * 2016-12-21 2020-12-09 Fred Hutchinson Cancer Research Center SCAFFOLDING TO TREAT SOLID TUMOR CELLS AND EXHAUST VARIANTS
JP7275031B2 (ja) * 2017-01-27 2023-05-17 ヤンセン バイオテツク，インコーポレーテツド Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
AU2018323053A1 (en) 2017-08-30 2020-03-19 Beijing Xuanyi Pharmasciences Co., Ltd Cyclic di-nucleotides as stimulator of interferon genes modulators
WO2020074004A1 (zh) * 2018-10-12 2020-04-16 上海济煜医药科技有限公司 环二核苷酸类化合物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096174A1 (en) * 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
TW201831192A (zh) * 2016-11-25 2018-09-01 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸

Also Published As

Publication number Publication date
TW201919650A (zh) 2019-06-01
JP2020532585A (ja) 2020-11-12
MX2020002303A (es) 2020-09-10
US11773132B2 (en) 2023-10-03
EP3692048A2 (en) 2020-08-12
AU2018323053A1 (en) 2020-03-19
KR20200058411A (ko) 2020-05-27
CA3073919A1 (en) 2019-03-07
RU2020112502A (ru) 2021-10-01
KR102782200B1 (ko) 2025-03-17
CN111263767A (zh) 2020-06-09
WO2019043634A2 (en) 2019-03-07
RU2020112502A3 (enExample) 2021-10-08
BR112020004047A2 (pt) 2020-09-01
JP7311514B2 (ja) 2023-07-19
CN111263767B (zh) 2023-07-18
WO2019043634A3 (en) 2019-04-11
US20200331957A1 (en) 2020-10-22
IL272928A (en) 2020-04-30
EP3692048A4 (en) 2021-10-20
SG11202001847WA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
TWI808092B (zh) 作為干擾素基因調節劑之刺激劑的環狀二核苷酸
US10961270B2 (en) Compounds and compositions for treating conditions associated with sting activity
JP6742534B2 (ja) 修飾環状ジヌクレオチド化合物
CN111989338A (zh) 修饰的环二核苷酸化合物
EP3856743A1 (en) Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
US20240066133A1 (en) Therapeutic agents and conjugates thereof
HK40022356A (en) Cyclic di-nucleotides as stimulator of interferon genes modulators
HK40022356B (en) Cyclic di-nucleotides as stimulator of interferon genes modulators
AU2010242394B2 (en) Purine derivative and antitumor agent using same